Status:
COMPLETED
Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
Lead Sponsor:
Istanbul University
Conditions:
Focal Segmental Glomerulosclerosis
Minimal Change Disease
Eligibility:
All Genders
18-80 years
Brief Summary
Various studies have been conducted to identify effective treatment strategies for primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) so far. In the light of these stud...
Eligibility Criteria
Inclusion
- Having biopsy-proven focal segmental glomerulosclerosis or minimal change disease.
- Showing resistance to or relapsing after at least one set of prior therapies including corticosteroids, calcineurin inhibitors or mycophenolic acid derivatives.
- Having a history of rituximab use (375 mg/m2/wk for 1-4 weeks) following resistance to or relapse after aforementioned agents.
Exclusion
- Not providing or withdrawing consent.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2020
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04369183
Start Date
September 1 2019
End Date
October 31 2020
Last Update
December 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul University
Istanbul, Turkey (Türkiye)